CellCarta, formely Caprion-HistoGeneX.
CellCarta is a leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late stage clinical trials.
The company operates globally with 9 facilities located in Canada, USA, Belgium, Australia, and China.
CellCarta is a leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late stage clinical trials.
The company operates globally with 9 facilities located in Canada, USA, Belgium, Australia, and China.
Location: Canada, Montreal (06), Montreal
Employees: 501-1000
Phone: +1 514-360-3600
Founded date: 2000
Investors 1
| Date | Name | Website |
| 27.01.2021 | Arsenal Ca... | arsenalcap... |
Mentions in press and media 8
| Date | Title | Description |
| 07.11.2025 | Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025 | Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a ... |
| 24.09.2025 | Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials | SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globa... |
| 21.06.2023 | Navigating IVDR: Challenges and Strategies for Clinical Trial Assay Development and Regulatory Submissions, Upcoming Webinar Hosted by Xtalks | Participants will gain insights into the classification of medical devices based on the rules outlined in Annex VIII of the IVDR. TORONTO, Ontario, Canada (PRWEB) June 21, 2023 Over the past year, in vitro diagnostic regulation (IVDR) has e... |
| 15.05.2023 | Predicting Immune Checkpoint Inhibitor Response Directly from Tumor RNA-Sequencing Data, Upcoming Webinar Hosted by Xtalks | There is an urgent need for robust predictive biomarkers for immune checkpoint inhibitor response to select patients with likely clinical benefit from this costly treatment. TORONTO (PRWEB) May 15, 2023 Immune checkpoint inhibitors (ICI) ha... |
| 19.05.2022 | CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays | This acquisition solidifies CellCarta's leadership position in proteomics services with a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein q... |
| 25.03.2022 | Qbic establishes third fund | St-Denijs-Westrem, Belgium, 17 March 2022 – Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, announces the first close of its third fund at € 49 millio... |
| 17.03.2022 | physIQ, CellCarta Collaborate on Study to Revolutionize Vaccine | What You Should Know: – Today, digital medicine leader physIQ and CellCarta, a global leader in precision medicine services announced they are collaborating on a groundbreaking study that could revolutionize vaccine development. – The strat... |
| 17.01.2022 | Fast, Metadata-Driven Analysis and Visualization of Flow and Mass Cytometry Data with CellEngine, Upcoming Webinar Hosted by Xtalks | A large variety of metadata-driven visualizations can be created, including ones combining categorical and continuous study metadata with the cytometry data. TORONTO (PRWEB) January 17, 2022 Common challenges faced with existing flow cytome... |